{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.1","upperLimit":"12.4","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"The distribution of time to progression will be estimated using the method of Kaplan-Meier. The International Myeloma Working Group (IMWG) uniform response criteria (Rajkumar et al, 2011) will be used to assess response to therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"4 arm A patients were transferred to Arm B for further treatment. Arm A patients, that went off study for any reason, were allowed to transfer to Arm B","id":"OG000","title":"Arms A and B"}],"paramType":"MEDIAN","populationDescription":"All patients that received Arm A or Arm B treatment.","reportingStatus":"POSTED","timeFrame":"Time from registration to the earliest date with documentation of disease progression, assessed up to 2 years","title":"Time to Progression","type":"SECONDARY","unitOfMeasure":"Months"}